Drug intelligence / Profile preview

BD200

Development stage: Phase 1
Lead developer: Biolojic Design
Modality: Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Antibody-Based Therapeutics

Overview

BD200 is a preclinical-stage multibody therapeutic being developed by Biolojic Design for the treatment of cancer. Utilizing the company's proprietary multibody platform, BD200 is designed to simultaneously target two undisclosed tumor-associated antigens (TAAs). This dual-targeting approach is intended to enhance tumor cell engagement and specificity, potentially improving therapeutic efficacy while minimizing off-target effects. As of early 2024, the program remains in the preclinical development phase.

Targets

PVRL4 (Nectin cell adhesion molecule 4)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on BD200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BD200.

Explore the full profile